【摘要】 目的对匹伐他汀治疗高胆固醇血症进行药物经济学评价,为科学制定用药方案提供依据,以促进合理用药及卫生资源的合理配置。方法采用基于马尔可夫模型的成本-效用分析评价匹伐他汀在有新发糖尿病风险下治疗高胆固醇血症的经济性。结果在均值估计基础上,匹伐他汀具有明显经济性,相比10 mg和20 mg阿托伐他汀,其期望成本更低的同时期望收益更高,具有绝对经济性;与成本较低的20 mg辛伐他汀治疗组相比,其增量成本效果比无论是否考虑年龄调整均低于世卫组织推荐的可接受标准[3倍中国人均国内生产总值(GDP)值,即156 000元],具有经济性。结论考虑避免新发糖尿病的治疗优势,匹伐他汀可以显现出经济性。更多还原

【Abstract】 Objective To conduct pharmacoeconomic evaluation of pitavastatin for hypercholesterolemia in order to provide scientific basis for developing treatment regimens and to promote rational drug use and rational allocation of health resources.Methods Cost-utility analysis based on Markov model was conducted to evaluate pitavastatin treatment for hypercholesterolemia with the risk of new-onset diabetes.Results On the basis of the estimated mean, pitavastatin has obvious economic advantage compared with atorvastatin of 10 mg and 20 mg. The cost of pitavastatin was lower but the expected utility was higher, showing absolute economy. When compared with simvastatin of 20 mg, the incremental cost effectiveness ratio were below acceptable standards recommended by WHO(three times of per capita GDP, ie 156,000 yuan), whether considering or not considering adjusted age.Conclusion If avoiding newonset diabetes is taken in into consideration, significant economic advantage of pitavastatin can be found.更多还原